SPEROGENIX

Sperogenix Therapeutics is a platform company dedicated to developing and commercializing rare disease therapeutics in China. With prioritized therapeutic areas, such as pulmonary vascular disorders, neuromuscular diseases, and inherited metabolic diseases, Sperogenix is dedicated to establishing an innovative commercial model tailored to the China rare disease field, in order to provide affordable and reliable products and services to Chinese physicians and patients. Sperogenix was founded in 2019 and is backed by biopharma industry blue chip investors including Lilly Asia Ventures and Morningside Ventures... Sperogenix Therapeutics is a platform focusing on development and commercialization of Rare Diseases Medications in China , provide clinically accessible products for rare disease patients and successful commercial solutions for rare disease therapeutics in China.

Also known as: Sperogenix Therapeutics Limited

Primary location: Beijing China